Search results
Utility of CTCA in CTO PCI
Added:
1 year ago
Article
Added:
6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an…
View more
Added:
1 year ago
Added:
6 months ago
Added:
1 year ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Prof Rosano summarises the retained ejection fraction…
View more
Added:
1 year ago
Added:
1 year ago
ESC-HFA 2023 — Prof Domingo Pascual Figal (Hospital Clinico Universitario Virgen de la Arrixaca, SP) discusses the DAPA MODA study (NCT04707352).
The study aimed to assess the effects of dapagliflozin on cardiac remodeling parameters, particularly LA geometry and function, and biomarkers reflecting pathophysiological pathways. Findings from ESC Heart Failure 2023 revealed that dapagliflozin…
View more
Added:
1 month ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Gabriele Gasparini
Job title: Interventional Cardiologist
Author
Max W Maffey
Author
